| 1 |
34620946 | Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway. | 2021 Oct 7 |
3 |
| 2 |
26400537 | Irbesartan attenuates TNF-α-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs. | 2015 Sep |
1 |
| 3 |
25016365 | Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. | 2014 Sep |
1 |
| 4 |
21575596 | Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade. | 2011 Jun 3 |
4 |
| 5 |
20668453 | A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects. | 2010 Oct |
1 |
| 6 |
15983321 | Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy. | 2005 Jul |
1 |
| 7 |
12626661 | Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. | 2003 Jun |
4 |